PLK2 and neoplasm: In this study, we analyzed the immunohistochemistry data of the tumor suppressor gene TAp73 and the tumor‐promoting gene PLK2 in clinical specimens and found that there is heterogeneity in the expression of TAp73 and PLK2 in OOS and COS cells, which affects the prognosis of patients.